Prognostic Biomarkers Of Pancreatic Cancer Based On Proteomics Techniques

Study Overview

Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

This study plan from the affiliated hospital of Qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.

Patients

JJDB-SR-2021-02

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2021-06-23	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2021-10-19
First Submitted that Met QC Criteria 2021-10-19	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2021-10-21
First Posted (ACTUAL) 2021-10-21	Results First Posted N/A	Last Verified 2021-10

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Differentially expressed proteins in tumor and paracancer tissues	Two dimensional gel electrophoresis, mass spectrometry and other techniques were used to separate and compare pancreatic cancer tissues and normal adjacent tissues to search for differentially expressed proteins.	180 Days

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Yu Cao, Doctor

Phone Number: 86-18661809090

Email: caoyu1767@126.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

Patients of Chinese nationality, age and gender are not limited.
Pathologically confirmed pancreatic cancer patients.
Pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer.
Clinical diagnostic information was complete three months before sampling.

Patients with a second primary tumor.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Yu Cao, Doctor, the study director of phase I clinical research center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

Patients

Caregivers

Clinical Trial Record